AMCA
VIR icon

Arthur M. Cohen & Associates’s Vir Biotechnology VIR Stock Holding History

Arthur M. Cohen & Associates’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,551
Closed -$234K – 140
2023
Q2 		$234K Buy
9,551
+373
+4% +$9.37K 0.06% 115
2023
Q1 		$214K Hold
9,178
– – 0.06% 118
2022
Q4 		$232K Buy
+9,178
New +$225K 0.06% 110
2022
Q2 		– Sell
-7,276
Closed -$305K – 143
2022
Q1 		$305K Hold
7,276
– – 0.06% 116
2021
Q4 		$305K Buy
7,276
+2,051
+39% +$80.4K 0.06% 125
2021
Q3 		$227K Buy
+5,225
New +$226K 0.05% 130

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arthur M. Cohen & Associates's VIR Position: Q3 2023 in Review

Arthur M. Cohen & Associates sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 9,551 shares — an estimated $234K sold.

Arthur M. Cohen & Associates first reported a position in VIR in Q3 2021 and held it in 6 quarters. The position peaked at $305K in Q1 2022. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Arthur M. Cohen & Associates reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Arthur M. Cohen & Associates sold 9,551 Vir Biotechnology shares in Q3 2023, an estimated $234K.
  • Arthur M. Cohen & Associates first reported a position in Vir Biotechnology in Q3 2021 and held it in 6 quarters.
  • Arthur M. Cohen & Associates's Vir Biotechnology position peaked at $305K in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Arthur M. Cohen & Associates's 13F filing for Q3 2023, filed 20 Oct 2023.